EMEA-001716-PIP05-20
Table of contents
Key facts
| Active substance |
Venglustat
|
| Therapeutic area |
|
| Decision number |
P/0505/2020
|
| PIP number |
EMEA-001716-PIP05-20
|
| Pharmaceutical form(s) |
Tablet
|
| Condition(s) / indication(s) |
Treatment of autosomal dominant polycystic kidney disease
|
| Route(s) of administration |
Oral use
|
| Contact for public enquiries |
Genzyme Europe B.V.
E-mail: eumedinfo.gz@sanofi.com |
| Decision type |
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
|